Apixa CCP Adverse Reactions

Common: Dermatologic: contusion (1.4% to 2.2%).
Gastrointestinal: bleeding gums (less than 0.1% to 1.4%).
Hematologic: hematoma (DVT 1.3% to 1.5%).
Reproductive: menorrhagia (1.4%).
Respiratory: bleeding from nose (DVT and pulmonary embolism 1.5% to 3.6%; DVT prophylaxis 0.1% to less than 1%), hemoptysis (less than 0.1% to 1.2%).
Serious: Gastrointestinal: gastrointestinal hemorrhage (atrial fibrillation 0.83%/year; DVT prophylaxis 0.1% to less than 1%; DVT and pulmonary embolism 0.1% to less than 1%), hematochezia (0.1% to less than 1%), rectal hemorrhage (less than 0.1% to 1%), upper gastrointestinal bleeding.
Hematologic: Hemorrhage (atrial fibrillation 2.08%/year; DVT prophylaxis 2.88% to 4.83%), hemorrhage (0.1% to 1.4%), hemorrhage, major (0.1% to 2.13%), hemorrhage, operative (DVT prophylaxis 0.1% to less than 1%).
Hepatic: Alkaline phosphatase raised (DVT prophylaxis 0.1% to less than 1%), liver function test abnormal (DVT prophylaxis 0.1% to less than 1%), serum bilirubin raised (DVT prophylaxis 0.1% to less than 1%).
Immunologic: hypersensitivity reaction (atrial fibrillation, less than 1%).
Musculoskeletal: hemorrhage of muscle (less than 0.1% to less than 1%).
Neurologic: extradural intracranial hematoma, intracranial hemorrhage (0.33% to 0.34% per year), non-traumatic spinal subdural hematoma, traumatic spinal subdural hematoma.
Ophthalmic: conjunctival hemorrhage (0.1% to less than 1%), retinal hemorrhage (0.1% to less than 1%).
Renal: hematuria (DVT 1.4% to 2.1%; DVT prophylaxis 0.1% to less than 1%).